US20190142820A1 - Drug for preventing and/or treating dementia - Google Patents

Drug for preventing and/or treating dementia Download PDF

Info

Publication number
US20190142820A1
US20190142820A1 US16/302,097 US201716302097A US2019142820A1 US 20190142820 A1 US20190142820 A1 US 20190142820A1 US 201716302097 A US201716302097 A US 201716302097A US 2019142820 A1 US2019142820 A1 US 2019142820A1
Authority
US
United States
Prior art keywords
dementia
app
cilostazol
taxifolin
transgenic mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/302,097
Other languages
English (en)
Inventor
Tadamasa MATSUMOTO
Masafumi Ihara
Satoshi Saito
Masanori Fukushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cerebral and Cardiovascular Center
Foundation for Biomedical Research and Innovation at Kobe
Original Assignee
National Cerebral and Cardiovascular Center
Foundation for Biomedical Research and Innovation at Kobe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cerebral and Cardiovascular Center, Foundation for Biomedical Research and Innovation at Kobe filed Critical National Cerebral and Cardiovascular Center
Assigned to FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, TADAMASA MATSUMOTO reassignment FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUKUSHIMA, MASANORI, IHARA, Masafumi, SAITO, SATOSHI, MATSUMOTO, TADAMASA
Publication of US20190142820A1 publication Critical patent/US20190142820A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a drug for preventing and/or treating dementia.
  • Dementia refers to a state in which organic change of the brain decreases memory function and other cognitive functions to the extent that the daily life is hindered.
  • the main causative disease of dementia includes Alzheimer-type dementia and vascular dementia.
  • Dementia includes core symptoms such as memory disorders, disorientation, dysexecutive function, agraphia, acalculia and the like, and behavioral and psychological symptoms of dementia (BPSD) such as anxiety, insomnia, increased aggression, depression, and disorders of wandering, delirium and the like.
  • BPSD behavioral and psychological symptoms of dementia
  • the spatial memory means the ability to grasp and memorize the state and relationship that an object occupies in a three-dimensional space, such as the position, direction, posture, size, shape, spacing and the like of the object, and the spatial memory disorder means disorder of such spatial memory.
  • the dysexecutive function is also called a disorder of working memory.
  • the working memory means the ability to keep information in mind for a short time and simultaneously process same, and the working memory disorder means disorder of such working memory.
  • Major causative disease of dementia includes Alzheimer-type dementia accompanying intracerebral amyloid plaque and vascular dementia caused by cerebrovascular disease.
  • the former has attracted attention as a disease occupying nearly half of all patients with dementia.
  • Cilostazol is an anti-platelet drug used for secondary prevention after cerebral infarction such as lacunar infarction and the like, and recently, the following actions thereof are also attracting attention. That is, it has been reported that administration of cilostazol shows actions that (i) intracerebral accumulation of amyloid beta (hereinafter sometimes abbreviated as A ⁇ ) is suppressed (non-patent documents 1, 2), (ii) reduction of cognitive function is suppressed (non-patent documents 1, 2), and (iii) cerebral blood flow in the vertebral artery, internal carotid artery, cerebral cortex, hypothalamus and the like increases (cilostazol package insert). Particularly, (i) is said to be related to the activation of cerebrovascular perivascular drainage pathway (brain interstitial flow), which is a waste discharge system in the brain.
  • a ⁇ amyloid beta
  • the cerebrovascular perivascular drainage pathway is a universal elimination pathway for not only A ⁇ but also neurotoxic substances such as tau protein, ⁇ -synuclein protein and the like.
  • Administration of cilostazol is expected to be effective for various cognitive disorders (e.g., Alzheimer-type dementia, frontotemporal lobar degeneration, Lewy body dementia etc.) caused by accumulation of many neurotoxic proteins.
  • cerebral blood flow decrease/cerebrovascular disorder is a factor that promotes the onset and progress of dementia.
  • administration of cilostazol has a positive effect on both the improvement of cerebral blood flow and the prevention of cerebral infarction.
  • Non-patent document 3 describes that, as a result of administration of a cilostazol-containing feed to APP-SwDI transgenic mice, an alternation response in the Y-maze test increased in APP-SwDI transgenic mice administered with cilostazol as compared to the APP-SwDI transgenic mouse administered with a control feed, and it is suggested that cilostazol is beneficial for improving working memory disorder in dementia.
  • the present invention aims to further improve the effect of a drug comprising cilostazol for preventing and/or treating dementia. Specifically, it aims to provide a drug effective not only for the core symptoms but also BPSD and effective even when the symptoms have progressed.
  • the drug for preventing and/or treating dementia of the present invention characteristically contains a carbostyril derivative represented by the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) or a salt thereof, and
  • dihydroquercetin or a salt thereof.
  • the drug for preventing and/or treating dementia of the present invention is characterized in that the active ingredient, a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) or a salt thereof, and
  • the active ingredient, dihydroquercetin or a salt thereof, are administered in combination.
  • a further effect for the prophylaxis and/or treatment of dementia is obtained than a single treatment of cilostazol.
  • FIG. 1 shows amounts of A ⁇ deposition on the cerebral vessel wall of the mice of each group.
  • FIG. 2 shows mean of relative increase rate of the cerebral blood flow after supply of 5% CO 2 in the mice of each group.
  • FIG. 3 shows an appearance of a circular pool used in a water maze test, wherein (A) is a cross sectional view and (B) is a top view.
  • FIG. 4 shows the results of a water maze test, wherein (A) shows mean of the total swimming distance of the mice of each group, (B) shows mean of the swimming time of the mice of each group, and (C) shows mean of the residence time in Zone-1 of the mice of each group in the probe test.
  • FIG. 5 shows a cumulative survival rate of the mice of each group.
  • FIG. 6 shows mean of the hair loss score of the mice of each group.
  • FIG. 7 shows the results of a Y-maze test.
  • the drug for preventing and/or treating dementia of the present embodiment contains a carbostyril derivative represented by the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) or a salt thereof, and
  • dihydroquercetin or a salt thereof.
  • the active ingredient of a carbostyril derivative represented by the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) or a salt thereof, and
  • the active ingredient of dihydroquercetin or a salt thereof are administered in combination.
  • the cycloalkyl group includes, for example, C 3 -C 8 cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Preferred cycloalkyl group is cyclohexyl.
  • the lower alkyl group includes, for example, C 1 -C 6 alkylene groups such as methylene, ethylene, propylene, tetramethylene, butylene and pentylene, with preference given to tetramethylene.
  • the drug of the present embodiment is used for preventing and/or treating dementia.
  • “preventing” includes suppressing and delaying the onset of a disease, and includes not only prevention before developing a disease but also prevention of recurrence of a disease after treatment.
  • “treatment” includes curing a symptom, improving a symptom and suppressing progress of a symptom.
  • Dementia is not particularly limited and includes, for example, Alzheimer-type dementia, Lewy body dementia, frontotemporal dementia, cerebrovascular dementia, Parkinson's disease, Down's syndrome, Huntington's disease and the like.
  • the drug of the present embodiment is used for preventing and/or treating dementia and can prevent and/or treat not only core symptoms of dementia but also BPSD caused by core symptoms.
  • BPSD emerge frequently as dementia progresses from moderate to severe.
  • BPSD include aggressive behavior, delusion, sleep disorder, wandering, resistance to nursing care, falling due to hyperactivity, suffocation by impulsive food stealing and the like.
  • the drug of the present embodiment contains a carbostyril derivative or a salt thereof, and dihydroquercetin or a salt thereof. It also includes a form of simultaneously or separately, or sequentially administering a combination of these. For example, a tablet or fine granule containing a carbostyril derivative as an active ingredient, and a tablet or fine granule containing dihydroquercetin as an active ingredient are combined, and the drug of the present embodiment also encompasses sequential administration of these.
  • the “drug containing a carbostyril derivative or a salt thereof, and dihydroquercetin or a salt thereof” is, for example, as follows.
  • a preferable carbostyril derivative is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril represented by the following formula (2), which is placed on the market under the trade name of cilostazol as an anti-platelet drug.
  • the average particle size of cilostazol is not particularly limited, it is preferably, for example, 10 ⁇ m-2000 ⁇ m. When the average particle size is larger than 2000 ⁇ m, an expensive equipment is required for preparing resin particles. When the average particle size is smaller than 10 ⁇ m, absorption in the lower gastrointestinal tract may be poor.
  • a salt of a carbostyril derivative can be easily formed by reacting with a pharmaceutically acceptable acid.
  • the acid include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like, and organic acids such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid and the like.
  • Carbostyril derivative and a salt thereof, and a production method thereof are disclosed in JP-A-55-35019 (corresponding U.S. Pat. No. 4,277,479).
  • Dihydroquercetin is a compound represented by the following formula (3).
  • Dihydroquercetin contains 4 kinds of stereoisomers due to the steric configurations of the 2-position and the 3-position.
  • a compound represented by the following formula (4), which is one kind thereof, is called taxifolin.
  • Dihydroquercetin also encompasses a dihydroquercetin derivative.
  • a dihydroquercetin derivative for example, a glycoside in which sugar is bonded to at least one hydroxyl group at the 3, 3′, 4′, 5 or 7-position of dihydroquercetin can be mentioned.
  • a salt of dihydroquercetin can be formed easily by reacting with a pharmaceutically acceptable acid.
  • examples of such salts include alkali metal salts such as sodium salt, potassium salt and the like.
  • Dihydroquercetin or a salt thereof can be produced by, for example, chemical synthesis or extraction from Siberian larch.
  • the mixing ratio of the carbostyril derivative and dihydroquercetin is not particularly limited, it can be set to, for example, 1:5-1:20 in weight ratio.
  • the dose of the active ingredient in the drug of the present embodiment can be appropriately determined according to the age, sex, body weight, symptom and the like of the patient. For example, 35-400 mg, preferably 100-200 mg, of a carbostyril derivative per day, and 150-2000 mg, preferably 500-1000 mg, of dihydroquercetin per day can be administered to an adult (body weight 50 kg) at once or in two to several divided portions.
  • the administration method of the drug of the present embodiment is not particularly limited and, for example, a carbostyril derivative and dihydroquercetin can be administered in combination simultaneously or separately, or sequentially with a time difference of several hours to several days. For sequential administration, either component may be administered first.
  • the drug of the present embodiment can be prepared into, for example, a preparation for oral administration such as tablet, granule, fine granule, capsule and the like, various liquid preparations suitable for oral administration, or a preparation for parenteral administration such as injection and suppository.
  • a preparation for oral administration such as tablet, granule, fine granule, capsule and the like
  • various liquid preparations suitable for oral administration or a preparation for parenteral administration such as injection and suppository.
  • a preparation for oral administration can be obtained by formulating a fine powder of the drug of the present embodiment, a dispersing agent and/or a dissolution improving agent together with a pharmaceutical carrier in the form of tablet, granule, fine granule, capsule or the like. Dispersibility and/or dissolution absorbability of the fine powder of the carbostyril derivative can be enhanced by adding a dispersing agent and/or dissolution improving agent.
  • excipient for example, sucrose, sodium chloride, mannitol, lactose, glucose, starch, calcium carbonate, kaolin, crystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose acetate succinate, silicate and the like can be used.
  • binder for example, water, ethanol, propanol, glucose solution, starch solution, gelatin solution, sodium carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, poly(vinyl alcohol), polyvinylpyrrolidone and the like can be used.
  • disintegrant for example, calcium carboxymethylcellulose, dry starch, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, stearic acid monoglyceride, starch, sodium carboxymethyl starch, croscarmellose sodium and the like can be used.
  • lubricant for example, purified talc, stearate salt, boric acid powder, polyethylene glycol, colloidal silicic acid, hydrogenated oil and the like can be used.
  • plasticizer for example, glycerol fatty acid ester, dioctylphthalate, dibutylphthalate, triacetin, triethyl citrate, castor oil and the like can be used.
  • water-soluble polymer for example, hydroxypropylcellulose, poly(vinyl alcohol), polyvinylpyrrolidone, hydroxypropylmethylcellulose, carboxymethylcellulose, polyacrylic acid and the like can be used.
  • alkylsulfate such as sodium lauryl sulfate, magnesium lauryl sulfate and the like
  • polyglycerol fatty acid ester such as decaglycerylmonolaurate, decaglycerylmonomyristate and the like
  • polyoxyethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monooleate and the like
  • polyethylene glycol fatty acid ester such as polyoxyethylene monostearate and the like
  • polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether and the like
  • polyoxyethylene castor oil such as polyoxyethylene hydrogenated castor oil and the like, and hydrogenated castor oil
  • sucrose fatty acid ester such as sucrose stearate, sucrose palmitate and the like, and the like can be used.
  • a dispersing agent and/or a dissolution improving agent per 1 part by weight of a fine powder of the drug of the present embodiment.
  • the amount of the dispersing agent and/or dissolution improving agent to be added is less than 0.001 part by weight, absorption becomes poor.
  • the amount to be added is higher than 100 parts by weight, the powder may be subject to toxicity such as mucosal damage and restriction by the Pharmaceutical Affairs Law.
  • Granule or fine granule can be prepared by adding the above-mentioned preparation carrier to a fine powder of the drug of the present embodiment, and granulating by fluidized bed granulation, high-speed stirring granulation, agitation fluidized bed granulating, centrifugal fluidizing granulation, extrusion-granulation and the like.
  • a capsule is prepared by mixing with an inactive pharmaceutical filler or diluent and packed in a hard gelatin capsule or soft capsule.
  • the average particle size of the drug of the present embodiment can be adjusted by using, for example, hammer mill, jet mill, rotary ball mill, vibrating ball mill, shaker mill, rod mill, tube mill and the like.
  • tablet, granule and fine granule can also be coated with a sustained-release coating base.
  • a sustained-release coating base cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, methacrylic acid copolymer, ethylcellulose and the like can be used. This makes it possible to provide, for example, a dissolution ability of the drug in the lower gastrointestinal tract.
  • An oral liquid preparation is prepared by mixing the drug of the present embodiment, and sweetener (e.g., sucrose), preservative (e.g., methylparaben, propylparaben), colorant, flavor and the like.
  • sweetener e.g., sucrose
  • preservative e.g., methylparaben, propylparaben
  • an injection preparation is prepared in the form of, for example, liquid, emulsion or suspension, and is isotonic to blood.
  • a preparation in the form of liquid, emulsion or suspension is prepared by using, for example, aqueous medium, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester.
  • aqueous medium water or a water-containing medium can be mentioned.
  • water sterile water is used. Examples of the water-containing medium include saline, PBS (phosphate buffered saline), lactated Ringer's solution and the like.
  • additives generally used in the technical field can be appropriately used.
  • the additive include isotonicity agent, stabilizer, buffering agent, preservative, chelating agent, antioxidant, solubilizing agents and the like.
  • isotonicity agent include saccharides such as glucose, sorbitol, mannitol and the like, sodium chloride, glycerol, propylene glycol, polyethylene glycol and the like.
  • stabilizer include sodium sulfite and the like.
  • buffering agent include borate buffering agent, phosphate buffering agent, citrate buffering agent, tartrate buffering agent, acetate buffering agent and the like.
  • Examples of the preservative include paraoxybenzoate, benzyl alcohol, chlorocresol, phenethyl alcohol, benzethonium chloride and the like.
  • Examples of the chelating agent include sodium edetate, sodium citrate and the like.
  • Examples of the antioxidant include sodium sulfite, sodium bisulfite, sodium ascorbate, sodium thiosulfate and the like.
  • Examples of the solubilizing agent include dextran, polyvinylpyrrolidone, sodium benzoate, ethylenediamine, salicylamide, nicotinamide, polyoxyethylene hydrogenated castor oil derivative and the like.
  • An injection preparation may contain a pH adjuster.
  • the pH adjuster may be acids or bases.
  • the acids include ascorbic acid, hydrochloric acid, gluconic acid, acetic acid, lactic acid, boric acid, phosphoric acid, sulfuric acid, tartaric acid, citric acid and the like.
  • the bases include potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide, monoethanolamine, diethanolamine, triethanolamine and the like.
  • the drug of the present embodiment can be applied to human as well as, for example, mammal other than human such as monkey, bovine, horse, swine, sheep, dog, cat, rat, mouse and the like.
  • the drug of the present embodiment has a remarkable effect exerted by a combination of a carbostyril derivative and dihydroquercetin. That is, as shown in the below-mentioned examples, cilostazol is effective for maintaining working memory but sometimes ineffective for maintaining spatial memory. However, the combined use of taxifolin renders cilostazol also effective for maintaining spatial memory. On the other hand, single administration of taxifolin sometimes develops an excitatory action (fighting etc.). Combined use of cilostazol sedates excitement. That is, it can effectively prevent onset of BPSD difficult to avoid by single administration of taxifolin, or a suppressive action and improving effect on the BPSD after the onset can be expected.
  • Antipsychotic agents, mood stabilizers, anti-anxiety drugs, sleep inducing drugs and the like are sometimes used for dementia patients to suppress their BPSD.
  • the drug of the present embodiment can accurately suppress BPSD, and the kind and amount of pharmaceutical products taken by patients can be expected to be reduced.
  • the drug of the present embodiment is effective for not only the core symptoms of dementia represented by memory disorders but also BPSD such as increased aggressiveness, anxiety and the like, and is extremely effective for the treatment of dementia.
  • the concentration of cilostazol in the cilostazol-containing feed was 0.3 wt %, and the concentration of taxifolin in the taxifolin-containing feed was 3 wt %.
  • the concentration of cilostazol and the concentration of taxifolin in the feed containing cilostazol and taxifolin were respectively 0.3 wt % and 3 wt %.
  • All the APP-SwDI transgenic mice used were homozygous male mice.
  • the 4-week-old APP-SwDI transgenic mice are considered to be in the initial stage of accumulation of A ⁇ in the brain blood vessel, i.e., the initial stage of cerebral amyloid angiopathy, and neuronal loss is considered to be not progressing much in this stage.
  • the brain of an 8-month-old APP-SwDI transgenic mice was perfusion fixed using 4% para-formaldehyde, the removed brain was dehydration-treated for a whole day.
  • a paraffin block of the fixed brain tissue was prepared, and the paraffin block was sliced in 6 microns by microtome.
  • a ⁇ deposition on the blood vessel wall was observed under a microscope by immunohistochemistry method for A ⁇ .
  • the hippocampus region was traced in a section which was cut 1 mm outside the midline, and the percentage of the A ⁇ accumulation area in the region of interest was measured by using image analysis software ImageJ (National Institutes of Health. USA).
  • FIG. 1 shows mean of the amount of A ⁇ deposition in each group of the mice. Error bars show standard deviation.
  • the APP-SwDI transgenic mice administrated with a cilostazol-containing feed, APP-SwDI transgenic mice administrated with a taxifolin-containing feed, and APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin showed a significant decrease in the intracerebral A ⁇ accumulation amount compared to the APP-SwDI transgenic mice administrated with a normal feed.
  • the concentration of cilostazol in the cilostazol-containing feed was 0.3 wt % and the concentration of taxifolin in the taxifolin-containing feed was 3 wt %. All the APP-SwDI transgenic mice used were homozygous male mice.
  • mice were anesthetized by intraperitoneal injection of ⁇ -chloralose and urethane. Then, endotracheal intubation was performed and the baseline of the cerebral blood flow was measured. Thereafter, 5% CO 2 was supplied, and the cerebral blood flow was sequentially measured for 5 min. Relative increase rate was measured from the changes in the cerebral blood flow between the baseline and after 5% CO 2 supply. The cerebral blood flow was measured by a laser speckle blood flow imager (OZ-2, OMEGAWAVE, INC.).
  • OZ-2 laser speckle blood flow imager
  • FIG. 2 is a graph showing mean of relative increase rate of the cerebral blood flow after supply of 5% CO 2 in the mice of each group.
  • the horizontal axis shows time (sec) after start of 5% CO 2 supply.
  • the open circle group shows C57BL/6J mice administrated with a normal feed
  • the square group shows APP-SwDI transgenic mice administrated with a normal feed
  • the triangle group shows APP-SwDI transgenic mice administrated with a cilostazol-containing feed
  • the rhombus group shows APP-SwDI transgenic mice administrated with a taxifolin-containing feed
  • the black circle group shows APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin. Error bars show standard error.
  • the increase rate of the cerebral blood flow decreased after 5% CO 2 supply as compared to the C57BL/6J mice.
  • the cerebral blood flow increase rate increased as compared to the APP-SwDI transgenic mice administrated with a normal feed.
  • the cilostazol-containing feed, the taxifolin-containing feed, and the feed containing cilostazol and taxifolin were administered from 4-week-old to 8-month-old.
  • the concentration of cilostazol in the cilostazol-containing feed was 0.3 wt %, and the concentration of taxifolin in the taxifolin-containing feed was 3 wt %.
  • the concentration of cilostazol and the concentration of taxifolin in the feed containing cilostazol and taxifolin were respectively 0.3 wt % and 3 wt %. All the APP-SwDI transgenic mice used were homozygous male mice.
  • the water maze test is a test for evaluating the visuospatial cognitive ability of mouse by utilizing the habit of avoiding water and escaping therefrom.
  • the water maze used in this experiment was Morris water maze manufactured by Brain Science Idea, having a circular pool of a water tank entirely painted black with inner diameter 120 cm, wall height 30 cm.
  • One transparent acrylic circular platform for escape with diameter 10 cm, height 10 cm was set at 30 cm from the center of the pool and 30 cm from the periphery.
  • Clues such as poster, photograph and the like were arranged on the wall so that the mice could memorize various spatial arrangements in the surroundings, and the locations of these clues were always unchanged during the experiment.
  • the pool was filled with water to a depth of 11 cm, and a platform was installed at about 1 cm below the water surface as in FIG. 3(A) .
  • Zone-2 in FIG. 3(B) was set as a start position.
  • Zone-1 to Zone-4 show quadrant regions in the circular pool. The mice were gently placed on the water surface while facing the wall of the pool so that they could not see the location of the platform.
  • the tests were performed from the first day to the fourth day, 4 trials per day. In each trial, the total swimming distance and the time required for reaching the platform (swimming time) were measured. When the mouse failed to reach on the platform within 60 seconds, the experimenter kept the mouse on the platform for 15 seconds and finished the test, and 60 seconds was taken as the swimming time of the mouse.
  • mice were made to swim for 60 seconds with the platform removed from the pool (probe test).
  • the residence time in Zone-1 where the goal was placed from the first day to the fourth day was measured.
  • FIG. 4(A) shows mean of the total swimming distance of the mice of each group from the first day to the fourth day
  • FIG. 4(B) shows mean of the time until the mice of each group reached the platform (swimming time) from the first day to the fourth day.
  • the horizontal axis shows number of trials for both.
  • the open circle group shows C57BL/6J mice administrated with a normal feed
  • the square group shows APP-SwDI transgenic mice administrated with a normal feed
  • the triangle group shows APP-SwDI transgenic mice administrated with a cilostazol-containing feed
  • the rhombus group shows APP-SwDI transgenic mice administrated with a taxifolin-containing feed
  • the black circle group shows APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin. Error bars show standard error.
  • mice of 5 groups In the mice of 5 groups, the total swimming distances did not show a significant difference, thus indicating that a significant difference was absent in the motility function of the mice.
  • the C57BL/6J mice shortened the time to reach the platform in each trial, whereas the time was not shortened in the APP-SwDI transgenic mice administrated with a normal feed, and a disorder of visuospatial memory was suggested.
  • This abnormality was the same as in the APP-SwDI transgenic mice administrated with a cilostazol-containing feed, and the visuospatial memory disorder improving effect of cilostazol was considered to be limited in the APP-SwDI transgenic mice.
  • the APP-SwDI transgenic mice administrated with a taxifolin-containing feed and the APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin showed the same results as in the C57BL/6J mouse.
  • taxifolin dramatically improves visuospatial memory disorder of APP-SwDI transgenic mice.
  • FIG. 4(C) shows mean (in seconds) of the residence time of the mice of each group in Zone-1 in a probe test in which the goal installed until then was removed. Error bars show standard error.
  • Zone-1 where the goal was originally installed was short in the APP-SwDI transgenic mice administrated with a normal feed as compared to the C57BL/6J mice, and a disorder of visuospatial memory was suggested.
  • This abnormality was the same as in the APP-SwDI transgenic mice administrated with a cilostazol-containing feed, and the visuospatial memory disorder improving effect of cilostazol was considered to be limited in the APP-SwDI transgenic mice.
  • the APP-SwDI transgenic mice administrated with a taxifolin-containing feed and the APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin showed the same results as in the C57BL/6J mouse. This has revealed that cilostazol and taxifolin improve visuospatial memory disorder of the APP-SwDI transgenic mice.
  • FIG. 5 shows a cumulative survival rate of the mice of each group on the vertical axis and the number of days after birth on the horizontal axis.
  • A shows a group of APP-SwDI transgenic mice administrated with a normal feed
  • B shows a group of APP-SwDI transgenic mice administrated with a cilostazol-containing feed
  • C shows a group of APP-SwDI transgenic mice administrated with a taxifolin-containing feed group
  • D shows a group of APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin.
  • the lifespan of a mouse is not less than two years, and it is comparatively rare that a mouse dies within 500 days under the observation at this time.
  • the APP-SwDI transgenic mice administrated with a taxifolin-containing feed died clearly more than other mice.
  • death of the mice was not seen in the APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin. This shows that the drug of this embodiment is also effective for the BPSD such as increased aggressiveness, anxiety and the like.
  • the information of mice was concealed and two evaluators independently evaluated the hair loss score. Mean of each evaluation was taken as the hair loss score of the mice.
  • FIG. 6 shows mean of the hair loss score of the mice of each group. Error bars show standard error.
  • the cilostazol-containing feed, the taxifolin-containing feed, and the feed containing cilostazol and taxifolin were administered from 4-week-old to 13-month-old.
  • the concentration of cilostazol in the cilostazol-containing feed was 0.3 wt %, and the concentration of taxifolin in the taxifolin-containing feed was 3 wt %.
  • the concentration of cilostazol and the concentration of taxifolin in the feed containing cilostazol and taxifolin were respectively 0.3 wt % and 3 wt %. All the APP-SwDI transgenic mice used were homozygous male mice.
  • FIG. 7 is a graph showing an average alternation response rate of the mice of each group. Error bars show standard error.
  • alternation response rate decreased in the APP-SwDI transgenic mice as compared to the C57BL/6J mice, thus suggesting disorder of working memory.
  • taxifolin administration mice significant improvement was not observed, and APP-SwDI transgenic mice administrated with a feed containing cilostazol and taxifolin showed a tendency toward increase in the alternation response. It was therefore shown that combined use of cilostazol and taxifolin can improve disorder of working memory of APP-SwDI transgenic mice even in a fairy advanced stage of dementia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US16/302,097 2016-05-19 2017-05-01 Drug for preventing and/or treating dementia Abandoned US20190142820A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016100092 2016-05-19
JP2016-100092 2016-05-19
PCT/JP2017/017195 WO2017199755A1 (fr) 2016-05-19 2017-05-01 Médicament pour prévenir et/ou traiter la démence

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/017195 A-371-Of-International WO2017199755A1 (fr) 2016-05-19 2017-05-01 Médicament pour prévenir et/ou traiter la démence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/126,488 Division US11925633B2 (en) 2016-05-19 2020-12-18 Drug for preventing and/or treating dementia

Publications (1)

Publication Number Publication Date
US20190142820A1 true US20190142820A1 (en) 2019-05-16

Family

ID=60326249

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/302,097 Abandoned US20190142820A1 (en) 2016-05-19 2017-05-01 Drug for preventing and/or treating dementia
US17/126,488 Active 2038-03-16 US11925633B2 (en) 2016-05-19 2020-12-18 Drug for preventing and/or treating dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/126,488 Active 2038-03-16 US11925633B2 (en) 2016-05-19 2020-12-18 Drug for preventing and/or treating dementia

Country Status (6)

Country Link
US (2) US20190142820A1 (fr)
EP (1) EP3459545A4 (fr)
JP (1) JP6872201B2 (fr)
KR (1) KR102181657B1 (fr)
CN (1) CN109310688B (fr)
WO (1) WO2017199755A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265603A1 (en) 2019-06-25 2022-08-25 National Hospital Organization Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
WO2008038849A1 (fr) * 2006-09-29 2008-04-03 Korea Institute Of Science And Technology Composition pharmaceutique comprenant un extrait d'opuntia ficus-indica
TWI423802B (zh) * 2007-05-22 2014-01-21 Otsuka Pharma Co Ltd 用於治療阿茲海默症之藥劑
DE102008029460A1 (de) * 2008-06-20 2009-12-31 Otkrytoe Aktsionernoe Obschestvo Zavod Ekologicheskoy Tekhniki I Ekopitaniya 'diod' Taxifolinderivate zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Störungen des zentralen Nervensystems
KR20120010800A (ko) * 2010-07-27 2012-02-06 인제대학교 산학협력단 실로스타졸 또는 이의 약리학적 허용가능한 염을 유효성분으로 함유하는 퇴행성 신경질환 치료 및 예방용 약학조성물
JP5715303B2 (ja) * 2012-06-15 2015-05-07 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤

Also Published As

Publication number Publication date
KR20190004336A (ko) 2019-01-11
EP3459545A4 (fr) 2020-02-26
WO2017199755A1 (fr) 2017-11-23
KR102181657B1 (ko) 2020-11-23
CN109310688B (zh) 2023-09-01
CN109310688A (zh) 2019-02-05
US20210100790A1 (en) 2021-04-08
JPWO2017199755A1 (ja) 2019-05-30
JP6872201B2 (ja) 2021-05-19
EP3459545A1 (fr) 2019-03-27
US11925633B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
US10016409B2 (en) Method for improving interstitial flow
JP2018035197A (ja) Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
US20210252173A1 (en) Stabilized polyunsaturated compounds and uses thereof
US20180193276A1 (en) Dosage forms of halofuginone and methods of use
CN108472275A (zh) 治疗缺血性中风的组合物及方法
US11925633B2 (en) Drug for preventing and/or treating dementia
CN112236140A (zh) 用于癌症治疗的使用异丁司特和第二药剂的方法和剂量方案
JP2021193126A (ja) ５′−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JP5459934B2 (ja) 神経接続欠陥、例えば精神分裂病及び自閉症の治療においてエポチロン（ｅｐｏｔｈｉｌｏｎｅ）を使用する方法
EP3813816B1 (fr) Utilisation de l'acide (s)-3-amino-4-(difluorométhylényl)cyclopent-1-ène-1-carboxylique et de composés apparentés, de l'acide (1s,3s)-3-amino-4-(difluorométhylidène)cyclopentane-1-carboxylique dans le traitement de le syndrome de l'x fragile ou le syndrome de tremblement/ataxie associé à l'x fragile
US20220265672A1 (en) Use of aprepitant for treating alzheimer's disease
US20160166536A1 (en) Combination therapy for the treatment of cancer
CN106232108A (zh) 治疗特发性肺纤维化的方法
US20240024332A1 (en) Apilimod compositions and methods of use
US20190201376A1 (en) Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases
CN118742299A (zh) 监测患者对视网膜氧化性疾病治疗反应的方法
KR20090119988A (ko) 만성 폐색성 폐질환 치료제

Legal Events

Date Code Title Description
AS Assignment

Owner name: TADAMASA MATSUMOTO, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATSUMOTO, TADAMASA;IHARA, MASAFUMI;SAITO, SATOSHI;AND OTHERS;SIGNING DATES FROM 20181015 TO 20181029;REEL/FRAME:047521/0947

Owner name: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATSUMOTO, TADAMASA;IHARA, MASAFUMI;SAITO, SATOSHI;AND OTHERS;SIGNING DATES FROM 20181015 TO 20181029;REEL/FRAME:047521/0947

Owner name: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATSUMOTO, TADAMASA;IHARA, MASAFUMI;SAITO, SATOSHI;AND OTHERS;SIGNING DATES FROM 20181015 TO 20181029;REEL/FRAME:047521/0947

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION